REGISTER
2026 Diabetes Consensus: 8 Key Updates for Cardio-Renal-Metabolic Care
A major new Chinese consensus updates the management of adults with type 2 diabetes and prediabetes, shifting practice from glucose control alone toward full cardio-renal-metabolic protection.

A new Chinese expert consensus has updated the prevention and management of atherosclerotic cardiovascular disease in adults with type 2 diabetes and prediabetes. The document shifts emphasis from glucose control alone toward comprehensive cardio-renal-metabolic protection.

Key updates

The consensus reaffirms standard diagnostic definitions for prediabetes and type 2 diabetes. It also recommends earlier screening, lowering the general-population screening age from 40 to 35 years.

In lifestyle management, it continues to emphasize diet, smoking cessation, sleep, and exercise, while newly stressing resistance training. Adults are advised to perform at least 150 to 300 minutes of moderate-intensity aerobic exercise each week plus resistance exercise two to three times weekly. Alcohol is no longer merely limited but generally not recommended.

Weight management is also refined. The target BMI remains 18.5 to 23.9 kg/m², but the new document gives clearer goals for weight loss, stronger support for modern weight-reducing drugs such as GLP-1-based therapies, and more detailed indications for metabolic surgery according to BMI.

In glucose management, the consensus encourages earlier combination therapy and stronger focus on cardio-renal benefit. It specifically highlights GLP-1 receptor agonists and SGLT2 inhibitors in patients with obesity, heart failure, chronic kidney disease, established ASCVD, or high cardiovascular risk.

Blood-pressure management is made more stratified and precise, with RAAS blockade remaining central and combination therapy recommended earlier in patients who are clearly above target or at high risk.

Lipid management continues to place LDL cholesterol at the center, with PCSK9 inhibitors, cholesterol-absorption inhibitors, and other newer agents available when statins are not enough or not tolerated.

The document also reiterates the importance of aspirin in secondary prevention, while urging cautious use in primary prevention after risk assessment.

Active protection against complications

A major theme of the 2026 consensus is active protection against complications. For chronic kidney disease, it explicitly supports combinations centered on ACE inhibitor or ARB therapy, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists. For heart failure, it highlights modern multidrug regimens. For metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea, it incorporates newer terminology, broader screening, and emerging therapeutic options.

Overall, the updated consensus reflects the trend toward individualized, multidimensional management of diabetes and prediabetes and is intended to improve cardiovascular, renal, and metabolic outcomes in routine clinical practice.

0
0
Loading